Neurizon Therapeutics (ASX: NUZ & OTCQB: NUZTF) has secured a multi-layered funding package designed to fully support its participation in the global HEALEY ALS Platform Trial, providing capital certainty through key clinical and regulatory milestones for its lead drug candidate, NUZ-001.
The company outlined firm commitments totalling approximately $7.1 million through a placement priced at $0.08 per share, alongside a 2-for-5 non-renounceable entitlement offer targeting up to $17.1 million. In parallel, Neurizon has established a $20 million strategic convertible note facility with New York-based investor Obsidian Global GP, LLC, offering staged access to capital over a two-year period.
Capital Structure Built Around Execution
The funding package is structured to align cash availability with clinical progress. Initial placement proceeds, combined with existing cash reserves and future R&D tax incentives, are expected to fund Neurizon’s full participation in both phases of the HEALEY ALS Platform Trial.
The Obsidian facility allows drawdowns to occur progressively, rather than upfront. This structure is intended to limit unnecessary dilution while preserving flexibility to pursue non-dilutive funding sources, including grants and regional licensing arrangements.
An initial $5 million drawdown is planned following shareholder approvals, with further tranches available subject to timing and capital conditions.
Positioning Within a Global ALS Development Framework
NUZ-001 will be evaluated within the HEALEY ALS Platform Trial, a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 study conducted in partnership with the Network of Excellence for ALS.
The platform design allows multiple investigational therapies to be assessed simultaneously, sharing infrastructure across trial sites. This approach is intended to improve enrolment efficiency and shorten development timelines compared with traditional single-asset trials.
Both the randomised clinical phase and the active treatment extension run for 36 weeks, enabling extended safety and efficacy assessment.
Broader Platform Ambitions for NUZ-001
Beyond ALS, Neurizon plans to deploy additional capital toward validating NUZ-001 as a broader neurodegenerative platform molecule. The company has flagged interest in indications such as Huntington’s disease and frontotemporal dementia, where overlapping disease mechanisms may allow clinical learnings to translate across programs.
Managing Director and CEO Dr Michael Thurn said: “This funding package fundamentally transforms Neurizon’s position and reflects the market’s recognition of NUZ-001 as a Phase 3-ready asset of international significance.”
The company expects to dose its first patient in the HEALEY ALS Platform Trial early in calendar year 2026, marking the transition from funding to execution.
